The Experts below are selected from a list of 135 Experts worldwide ranked by ideXlab platform
Tetsuya Tateishi - One of the best experts on this subject based on the ideXlab platform.
-
Investigations on the interaction of Tartaric Acid Derivative/human serum albumin tissue adhesive with J774A.1 mouse macrophage cells through SEM, IL-6 cytokine and gene expression techniques.
Bio-medical Materials and Engineering, 2020Co-Authors: Rao Sethumadhavan, Tetsushi Taguchi, Junzo Tanaka, Tetsuya TateishiAbstract:: We developed a novel tissue adhesive consisting of human serum albumin (HSA) and Tartaric Acid Derivative (TAD). Four different concentrations of TAD namely, 0.05 mM, 0.1 mM, 0.2 mM and 0.3 mM were mixed with 40%, 42% and 44% HSA individually and were made in the form of disks. J774A.1 mouse macrophage cells were seeded on top of these disks. The disks were pre-treated with sterile water and Eagle's medium before every seeding. All the seeding was incubated from 1 day to 3 days before making any investigations on it. SEM images were recorded and it was observed that these cells adhered to these materials very well. Mouse IL-6 cytokine expressions were studied using ELISA. It was seen from the cytokine expression results that the release of IL-6 was minimum at 0.3 mM TAD concentrations with 44% HSA disks. No significant difference was observed in the cytokine expressions of IL-6 at 42% and 44% HSA at all concentrations of TAD studied in this work. mRNA gene expressions of IL-6 were investigated using RT-PCR technique. In 40% HSA, the gene expression level of IL-6 gene did not change during 3-day-culture in the range of TAD concentration of 0.05 mmol to 0.2 mmol. However, 0.3 mM TAD suppressed the gene expression at all concentration of HSA. In 42% HSA, although 0.05 mM and 0.1 mM TAD did not affect the gene expression, 0.2 mM and 0.3 mM TAD induced the expression level with incubation time. In 44% HSA, all the concentration of TAD increased the expression level even though the cytokine expression levels were quite low. Hence it could be thought that the expression at the cytokine level is quite insignificant where as it is to be considered at the gene expression level. On the whole, 0.3 mM TAD with 44% HSA could be considered as a challenging material as a tissue adhesive material for use in the field of tissue engineering.
-
in vivo evaluation of bonding ability and biocompatibility of a novel biodegradable glue consisting of Tartaric Acid Derivative and human serum albumin
Journal of Biomedical Materials Research Part A, 2009Co-Authors: Tetsushi Taguchi, Masashi Iwasashi, Masataka Sakane, Hirofumi Saito, Tetsuya Tateishi, Naoyuki OchiaiAbstract:We recently developed a novel biological glue from Tartaric Acid Derivative (TAD) with two active ester groups and human serum albumin (HSA), named TAD-A. In this study, in vivo experiments were performed to investigate clinical applicability of TAD-A. TAD was prepared by reacting carboxyl groups of Tartaric Acid with N-hydroxysuccinimide in the presence of carbodiimide. Bonding strength was evaluated by using mouse skin closed with TAD-A of different TAD concentrations from 0.1 to 0.5 mmol in 0.8 mg of 44 w/w % HSA solution. Commercially available glues such as fibrin and aldehyde-based glue were used for comparison. We found that TAD-A's bonding strength increased significantly with TAD-A concentration. The bonding strength of 0.5 mmol of TAD-A in 0.8 mg of 44 w/w % HSA solution was significantly higher than that of fibrin or aldehyde-based glue (p < 0.01), and that of 0.3 mmol of TAD-A was significantly higher than of fibrin glue (p < 0.05). To determine toxicity, we implanted disks made from TAD-A of different TAD concentrations from 0.1 to 0.5 mmol in 0.8 mg of 44 w/w % HSA solution subcutaneously in mice. The inflammatory reaction in surrounding tissue increased with increasing TAD concentration, and then the disks were absorbed. In conclusion, TAD-A has sufficient bonding strength and comparatively low toxicity in clinical use of 0.3 mmol or less of TAD and 0.8 mL of 44 w/w % HSA solution.
-
investigations on the interaction of Tartaric Acid Derivative human serum albumin tissue adhesive with j774a 1 mouse macrophage cells through sem il 6 cytokine and gene expression techniques
Bio-medical Materials and Engineering, 2007Co-Authors: Rao Sethumadhavan, Tetsushi Taguchi, Junzo Tanaka, Tetsuya TateishiAbstract:: We developed a novel tissue adhesive consisting of human serum albumin (HSA) and Tartaric Acid Derivative (TAD). Four different concentrations of TAD namely, 0.05 mM, 0.1 mM, 0.2 mM and 0.3 mM were mixed with 40%, 42% and 44% HSA individually and were made in the form of disks. J774A.1 mouse macrophage cells were seeded on top of these disks. The disks were pre-treated with sterile water and Eagle's medium before every seeding. All the seeding was incubated from 1 day to 3 days before making any investigations on it. SEM images were recorded and it was observed that these cells adhered to these materials very well. Mouse IL-6 cytokine expressions were studied using ELISA. It was seen from the cytokine expression results that the release of IL-6 was minimum at 0.3 mM TAD concentrations with 44% HSA disks. No significant difference was observed in the cytokine expressions of IL-6 at 42% and 44% HSA at all concentrations of TAD studied in this work. mRNA gene expressions of IL-6 were investigated using RT-PCR technique. In 40% HSA, the gene expression level of IL-6 gene did not change during 3-day-culture in the range of TAD concentration of 0.05 mmol to 0.2 mmol. However, 0.3 mM TAD suppressed the gene expression at all concentration of HSA. In 42% HSA, although 0.05 mM and 0.1 mM TAD did not affect the gene expression, 0.2 mM and 0.3 mM TAD induced the expression level with incubation time. In 44% HSA, all the concentration of TAD increased the expression level even though the cytokine expression levels were quite low. Hence it could be thought that the expression at the cytokine level is quite insignificant where as it is to be considered at the gene expression level. On the whole, 0.3 mM TAD with 44% HSA could be considered as a challenging material as a tissue adhesive material for use in the field of tissue engineering.
-
Injectable in situ forming drug delivery system for cancer chemotherapy using a novel tissue adhesive: characterization and in vitro evaluation.
European Journal of Pharmaceutics and Biopharmaceutics, 2006Co-Authors: Sachiro Kakinoki, Tetsushi Taguchi, Hirofumi Saito, Junzo Tanaka, Tetsuya TateishiAbstract:Abstract Injectable polymers that are biocompatible and biodegradable are important biomaterials for drug delivery system (DDS) and tissue engineering. We have already developed novel tissue adhesives consisting of biomacromolecules and organic Acid Derivatives with active ester groups. The resulting tissue adhesive forms in situ as a gel and has high bonding strength for living tissue as well as it has good biocompatibility and biodegradability. Here, we report on the physicochemical properties and in vitro evaluation of this novel tissue adhesive consisting of human serum albumin (HSA) and Tartaric Acid Derivative (TAD) containing doxorubicin hydrochloride (DOX). The results of the measurement of physicochemical characteristics indicate that the gelation time and gel strength of HSA–TAD gels can be controlled according to the material composition. The bonding strength of HSA–TAD adhesives was found to be sufficient to adhere at focus and to correspond with the cross-linking density of HSA–TAD gels. Furthermore, the release of DOX from HSA–TAD gels was sustained for approximately 100 h in an in vitro evaluation. The novel tissue adhesive, therefore, is expected to be applicable for use as an injectable in situ forming DDS.
Tetsushi Taguchi - One of the best experts on this subject based on the ideXlab platform.
-
Investigations on the interaction of Tartaric Acid Derivative/human serum albumin tissue adhesive with J774A.1 mouse macrophage cells through SEM, IL-6 cytokine and gene expression techniques.
Bio-medical Materials and Engineering, 2020Co-Authors: Rao Sethumadhavan, Tetsushi Taguchi, Junzo Tanaka, Tetsuya TateishiAbstract:: We developed a novel tissue adhesive consisting of human serum albumin (HSA) and Tartaric Acid Derivative (TAD). Four different concentrations of TAD namely, 0.05 mM, 0.1 mM, 0.2 mM and 0.3 mM were mixed with 40%, 42% and 44% HSA individually and were made in the form of disks. J774A.1 mouse macrophage cells were seeded on top of these disks. The disks were pre-treated with sterile water and Eagle's medium before every seeding. All the seeding was incubated from 1 day to 3 days before making any investigations on it. SEM images were recorded and it was observed that these cells adhered to these materials very well. Mouse IL-6 cytokine expressions were studied using ELISA. It was seen from the cytokine expression results that the release of IL-6 was minimum at 0.3 mM TAD concentrations with 44% HSA disks. No significant difference was observed in the cytokine expressions of IL-6 at 42% and 44% HSA at all concentrations of TAD studied in this work. mRNA gene expressions of IL-6 were investigated using RT-PCR technique. In 40% HSA, the gene expression level of IL-6 gene did not change during 3-day-culture in the range of TAD concentration of 0.05 mmol to 0.2 mmol. However, 0.3 mM TAD suppressed the gene expression at all concentration of HSA. In 42% HSA, although 0.05 mM and 0.1 mM TAD did not affect the gene expression, 0.2 mM and 0.3 mM TAD induced the expression level with incubation time. In 44% HSA, all the concentration of TAD increased the expression level even though the cytokine expression levels were quite low. Hence it could be thought that the expression at the cytokine level is quite insignificant where as it is to be considered at the gene expression level. On the whole, 0.3 mM TAD with 44% HSA could be considered as a challenging material as a tissue adhesive material for use in the field of tissue engineering.
-
in vivo evaluation of bonding ability and biocompatibility of a novel biodegradable glue consisting of Tartaric Acid Derivative and human serum albumin
Journal of Biomedical Materials Research Part A, 2009Co-Authors: Tetsushi Taguchi, Masashi Iwasashi, Masataka Sakane, Hirofumi Saito, Tetsuya Tateishi, Naoyuki OchiaiAbstract:We recently developed a novel biological glue from Tartaric Acid Derivative (TAD) with two active ester groups and human serum albumin (HSA), named TAD-A. In this study, in vivo experiments were performed to investigate clinical applicability of TAD-A. TAD was prepared by reacting carboxyl groups of Tartaric Acid with N-hydroxysuccinimide in the presence of carbodiimide. Bonding strength was evaluated by using mouse skin closed with TAD-A of different TAD concentrations from 0.1 to 0.5 mmol in 0.8 mg of 44 w/w % HSA solution. Commercially available glues such as fibrin and aldehyde-based glue were used for comparison. We found that TAD-A's bonding strength increased significantly with TAD-A concentration. The bonding strength of 0.5 mmol of TAD-A in 0.8 mg of 44 w/w % HSA solution was significantly higher than that of fibrin or aldehyde-based glue (p < 0.01), and that of 0.3 mmol of TAD-A was significantly higher than of fibrin glue (p < 0.05). To determine toxicity, we implanted disks made from TAD-A of different TAD concentrations from 0.1 to 0.5 mmol in 0.8 mg of 44 w/w % HSA solution subcutaneously in mice. The inflammatory reaction in surrounding tissue increased with increasing TAD concentration, and then the disks were absorbed. In conclusion, TAD-A has sufficient bonding strength and comparatively low toxicity in clinical use of 0.3 mmol or less of TAD and 0.8 mL of 44 w/w % HSA solution.
-
surface modification of sus 316l stainless steel with Tartaric Acid Derivative crosslinked human serum albumin matrices
The Open Biotechnology Journal, 2008Co-Authors: Sachiro Kakinoki, Yasuyuki Katada, Yoshiyuki Uchida, Tetsushi TaguchiAbstract:The surface of stainless steel (SUS316L) was modified by alternating immersion in a solution of human serum albumin (HSA) and solution of a Tartaric Acid Derivative (TAD). The resulting HSA/TAD-immobilized SUS316L was characterized by means of contact-angle measurement, attenuated total-reflectance Fourier-transform infrared spectros- copy, atomic force microscopy, and X-ray photoelectron spectroscopy. A HSA/TAD layer was formed on the surface of SUS316L, the thickness of which increased with increasing numbers of cycles of alternating immersion in the two solu- tions. The HSA/TAD layer on SUS316L was stable to washing in 1 M NaCl or 5 vol% sodium dodecyl sulfate, showing that the layer was immobilized by covalent bonding rather than electrostatic or hydrophobic interaction. The presence of the HSA/TAD layer on the SUS316L suppressed the formation of a fibrin network. Alternating immersion in solutions of HSA and TAD is a useful technique for functionalizing the surfaces of metals.
-
Antitumor effect of an injectable in-situ forming drug delivery system composed of a novel tissue adhesive containing doxorubicin hydrochloride.
European Journal of Pharmaceutics and Biopharmaceutics, 2007Co-Authors: Sachiro Kakinoki, Tetsushi TaguchiAbstract:Abstract Our group has developed a novel tissue adhesive composed of biomacromolecules and organic Acid Derivatives which have good biocompatibility and exhibit high bonding strength to living tissues. We propose to use this tissue adhesive for in-situ forming drug delivery system (DDS) for cancer chemotherapy. In a previous work, we had prepared a novel in-situ forming DDS composed of human serum albumin (HSA) and Tartaric Acid Derivative (TAD) containing doxorubicin hydrochloride (DOX), and we had demonstrated an in vitro release profile of DOX from HSA–TAD gel for approximately up to 100 h. Here, we report on antitumor effect of this injectable in-situ forming DDS. Local injection of DOX by the HSA–TAD was administered to human colon carcinoma (WiDr) implanted subcutaneously onto the immunodeficient mouse. The results of the in vivo experiments showed that the presence of DOX in blood of mice was detectable for up to 3 days, and that the tumor volume was effectively minimized with injection of HSA–TAD containing DOX. The in-situ forming DDS with the novel tissue adhesive containing DOX, therefore, is a useful technique for cancer chemotherapy.
-
investigations on the interaction of Tartaric Acid Derivative human serum albumin tissue adhesive with j774a 1 mouse macrophage cells through sem il 6 cytokine and gene expression techniques
Bio-medical Materials and Engineering, 2007Co-Authors: Rao Sethumadhavan, Tetsushi Taguchi, Junzo Tanaka, Tetsuya TateishiAbstract:: We developed a novel tissue adhesive consisting of human serum albumin (HSA) and Tartaric Acid Derivative (TAD). Four different concentrations of TAD namely, 0.05 mM, 0.1 mM, 0.2 mM and 0.3 mM were mixed with 40%, 42% and 44% HSA individually and were made in the form of disks. J774A.1 mouse macrophage cells were seeded on top of these disks. The disks were pre-treated with sterile water and Eagle's medium before every seeding. All the seeding was incubated from 1 day to 3 days before making any investigations on it. SEM images were recorded and it was observed that these cells adhered to these materials very well. Mouse IL-6 cytokine expressions were studied using ELISA. It was seen from the cytokine expression results that the release of IL-6 was minimum at 0.3 mM TAD concentrations with 44% HSA disks. No significant difference was observed in the cytokine expressions of IL-6 at 42% and 44% HSA at all concentrations of TAD studied in this work. mRNA gene expressions of IL-6 were investigated using RT-PCR technique. In 40% HSA, the gene expression level of IL-6 gene did not change during 3-day-culture in the range of TAD concentration of 0.05 mmol to 0.2 mmol. However, 0.3 mM TAD suppressed the gene expression at all concentration of HSA. In 42% HSA, although 0.05 mM and 0.1 mM TAD did not affect the gene expression, 0.2 mM and 0.3 mM TAD induced the expression level with incubation time. In 44% HSA, all the concentration of TAD increased the expression level even though the cytokine expression levels were quite low. Hence it could be thought that the expression at the cytokine level is quite insignificant where as it is to be considered at the gene expression level. On the whole, 0.3 mM TAD with 44% HSA could be considered as a challenging material as a tissue adhesive material for use in the field of tissue engineering.
Naoyuki Ochiai - One of the best experts on this subject based on the ideXlab platform.
-
in vivo evaluation of bonding ability and biocompatibility of a novel biodegradable glue consisting of Tartaric Acid Derivative and human serum albumin
Journal of Biomedical Materials Research Part A, 2009Co-Authors: Tetsushi Taguchi, Masashi Iwasashi, Masataka Sakane, Hirofumi Saito, Tetsuya Tateishi, Naoyuki OchiaiAbstract:We recently developed a novel biological glue from Tartaric Acid Derivative (TAD) with two active ester groups and human serum albumin (HSA), named TAD-A. In this study, in vivo experiments were performed to investigate clinical applicability of TAD-A. TAD was prepared by reacting carboxyl groups of Tartaric Acid with N-hydroxysuccinimide in the presence of carbodiimide. Bonding strength was evaluated by using mouse skin closed with TAD-A of different TAD concentrations from 0.1 to 0.5 mmol in 0.8 mg of 44 w/w % HSA solution. Commercially available glues such as fibrin and aldehyde-based glue were used for comparison. We found that TAD-A's bonding strength increased significantly with TAD-A concentration. The bonding strength of 0.5 mmol of TAD-A in 0.8 mg of 44 w/w % HSA solution was significantly higher than that of fibrin or aldehyde-based glue (p < 0.01), and that of 0.3 mmol of TAD-A was significantly higher than of fibrin glue (p < 0.05). To determine toxicity, we implanted disks made from TAD-A of different TAD concentrations from 0.1 to 0.5 mmol in 0.8 mg of 44 w/w % HSA solution subcutaneously in mice. The inflammatory reaction in surrounding tissue increased with increasing TAD concentration, and then the disks were absorbed. In conclusion, TAD-A has sufficient bonding strength and comparatively low toxicity in clinical use of 0.3 mmol or less of TAD and 0.8 mL of 44 w/w % HSA solution.
Rikard C Unelius - One of the best experts on this subject based on the ideXlab platform.
-
preparation characterization and application of a stationary chromatographic phase from a new Tartaric Acid Derivative
Tetrahedron Letters, 2010Co-Authors: Sacha Legrand, Harri Heikkinen, Ian A Nicholls, Andrew Root, Johan Svenson, Rikard C UneliusAbstract:The preparation, characterization and application of a new stationary phase derived from 1,4-cyclohexanedione and diethyl (+)-tartrate are described. A suitable TADDOL for immobilization has been s ...
Masashi Iwasashi - One of the best experts on this subject based on the ideXlab platform.
-
in vivo evaluation of bonding ability and biocompatibility of a novel biodegradable glue consisting of Tartaric Acid Derivative and human serum albumin
Journal of Biomedical Materials Research Part A, 2009Co-Authors: Tetsushi Taguchi, Masashi Iwasashi, Masataka Sakane, Hirofumi Saito, Tetsuya Tateishi, Naoyuki OchiaiAbstract:We recently developed a novel biological glue from Tartaric Acid Derivative (TAD) with two active ester groups and human serum albumin (HSA), named TAD-A. In this study, in vivo experiments were performed to investigate clinical applicability of TAD-A. TAD was prepared by reacting carboxyl groups of Tartaric Acid with N-hydroxysuccinimide in the presence of carbodiimide. Bonding strength was evaluated by using mouse skin closed with TAD-A of different TAD concentrations from 0.1 to 0.5 mmol in 0.8 mg of 44 w/w % HSA solution. Commercially available glues such as fibrin and aldehyde-based glue were used for comparison. We found that TAD-A's bonding strength increased significantly with TAD-A concentration. The bonding strength of 0.5 mmol of TAD-A in 0.8 mg of 44 w/w % HSA solution was significantly higher than that of fibrin or aldehyde-based glue (p < 0.01), and that of 0.3 mmol of TAD-A was significantly higher than of fibrin glue (p < 0.05). To determine toxicity, we implanted disks made from TAD-A of different TAD concentrations from 0.1 to 0.5 mmol in 0.8 mg of 44 w/w % HSA solution subcutaneously in mice. The inflammatory reaction in surrounding tissue increased with increasing TAD concentration, and then the disks were absorbed. In conclusion, TAD-A has sufficient bonding strength and comparatively low toxicity in clinical use of 0.3 mmol or less of TAD and 0.8 mL of 44 w/w % HSA solution.
